| View |
|
BR-1280
|
Atezolizumab
|
Tecentriq
|
60 mg/mL (1.2 g/20 mL)
|
Concentrate for Solution for
Infusion
|
Prescription Drug (RX)
|
Type I glass vial with rubber stopper and aluminum
seal with flip-off cap x 20 mL (Box of 1's)
|
-
|
Roche Diagnostics GmbH
|
Germany
|
N/A
|
Roche (Philippines) Inc.
|
N/A
|
Monitored Release (Variation)
|
22 February 2023
|
22 February 2028
|
| View |
|
BR-1282
|
Eptacog alfa activated
|
NovoSeven RT
|
1 mg/vial (50KIU/vial)
|
Powder And Solvent For Solution For Injection
|
Prescription Drug (RX)
|
Vial: Type I glass vial closed with chlorobutyl rubber stopper, covered with an aluminium cap. The closed vial is equipped with a polypropylene tamper-evident snap-off cap. Pre-filled syringe: Type I glass barrel with a polypropylene backstop and bromobutyl rubber plunger. The syringe cap consists of bromobutyl rubber and polypropylene tamper evident seal. Plunger rod: made of polypropylene.
|
Blood Coagulation Factor
|
Novo Nordisk A/S
|
Denmark
|
|
Novo Nordisk Pharmaceuticals (Philippines) Inc.
|
|
Renewal
|
01 August 2023
|
25 July 2028
|
| View |
|
BR-1284
|
Isophane Insulin (Recombinant DNA)
|
Humulin N
|
100 Units/mL
|
Suspension for Injection (SC)
|
Prescription Drug (RX)
|
Type I siliconized glass cartridge sealed with rubber closures consisting of a chlorobutyl plunger and an aluminum disc seal x 3 mL (Box of 5's)
|
-
|
Lilly France S.A.S.
|
France
|
N/A
|
Zuellig Pharma Corporation
|
Zuellig Pharma Corporation
|
Renewal
|
11 October 2022
|
31 October 2027
|
| View |
|
BR-1290
|
Inactivated Poliomyelitis Vaccine (Types 1, 2 And 3)
|
Poliovac
|
0.5 mL
|
Suspension For Injection (IM/SC)
|
Prescription Drug (RX)
|
Type I Clear Vial x 0.5 mL (Box of 1's, 10's and 50's)
|
-
|
Serum Institute of India Private Limited
|
India
|
N/A
|
Faberco Life Sciences Inc.
|
Faberco Life Sciences Inc.
|
Initial (Variation)
|
09 February 2023
|
09 February 2028
|
| View |
|
BR-1296
|
Dulaglutide
|
Trulicity
|
0.75 mg/0.5 mL
|
Solution For Injection
|
Prescription Drug (RX)
|
0.5 mL Type I glass syringe barrel with 29 G x 1/2" needle in a pen delivery device (Box of 4's)
|
Antidiabetic
|
Eli Lilly and Company
|
United States of America
|
|
Zuellig Pharma Corp.
|
|
Monitored Release
|
08 October 2019
|
18 June 2025
|
| View |
BR-1297_PI_01.pdf
|
BR-1297
|
Dulaglutide
|
Trulicity
|
1.5 mg/0.5 mL
|
Solution For Injection
|
Prescription Drug (Rx)
|
0.5 mL Type I glass syringe barrel with 29 G x 1/2" needle in a pen delivery device (Box of 4's)
|
Antidiabetic
|
Eli Lilly and Company
|
United States of America
|
|
Zuellig Pharma Corp.
|
|
Monitored Release
|
08 October 2019
|
18 June 2025
|
| View |
BR-1299_PI_01.pdf
|
BR-1299
|
Ixekizumab
|
Taltz
|
80mg/mL
|
Solution For Injection (SC)
|
Prescription Drug (RX)
|
1 mL Type I Clear Glass Syringe Barrel, with 27g X 1/2" Needle, in a Pen delivery device (Box of l's, 2's, and 3's + Physician Sample). Single dose.
|
Interleukin Inhibitor
|
Eli Lilly & Company
|
United States of America
|
|
Zuellig Pharma Corporation
|
Zuellig Pharma Corporation
|
Monitored Release
|
17 March 2022
|
08 July 2025
|
| View |
BR-1300_PI_01.pdf
|
BR-1300
|
Ixekizumab
|
Taltz
|
80mg/mL
|
Solution For Injection (SC)
|
Prescription Drug (RX)
|
1mL Type I clear prefilled glass syringe with 27 G 1/2 needle (Box of 1's, 2's and 3's). Single dose.
|
Interleukin Inhibitor
|
Eli Lilly & Company
|
United States of America
|
|
Zuellig Pharma Corporation
|
Zuellig Pharma Corporation
|
Monitored Release
|
17 March 2022
|
08 July 2025
|
| View |
|
BR-1303
|
Hepatitis A (Inactivated) Vaccine (Adsorbed)
|
Havrix 720
|
720 ELISA units/0.5 mL
|
Suspension for Injection (IM)
|
Prescription Drug (Rx)
|
Type I pre-filled glass syringe x 0.5 mL, with separate
needle, packed in a blister (Box of 1's)
|
Vaccine
|
GlaxoSmithKline Biologicals SA
|
Belgium
|
|
GlaxoSmithKline Philippines, Inc.
|
|
Initial (Variation)
|
28 June 2024
|
28 June 2029
|
| View |
|
BR-1304
|
Hepatitis A (Inactivated) Vaccine (Adsorbed)
|
Havrix 1440
|
1440 ELISA units/mL
|
Suspension For Injection (IM)
|
Prescription Drug (RX)
|
Type I pre-filled glass syringe x 1mL, with separate needle, packed in a blister (Box of 1's)
|
Vaccine
|
GlazoSmithKlineBiologicals SA
|
Belgium
|
|
GlaxoSmithKline Philippines, Inc.
|
|
Renewal
|
31 May 2024
|
14 August 2029
|
| View |
|
BR-1308
|
Pneumococcal Conjugate Vaccine, 13-Valent (adsorbed) [See formulation]
|
Prevenar 13
|
0.5 mL per dose
|
Suspension For Im Injection
|
Prescription Drug (RX)
|
2 mL pre-filled borosilicate glass vial (Type I) with chlorobutyl rubber stopper, aluminum seal and light blue flip off cap and vaccine vial monitor (box of 50's); Multi-dose (0.5 mL per dose)
|
Vaccine
|
Pfizer Manufacturing Belgium NV
|
Belgium
|
|
Pfizer, Inc
|
Pfizer, Inc
|
Renewal
|
07 October 2024
|
05 December 2029
|
| View |
BR-1311_PI_01.pdf
|
BR-1311
|
Ustekinumab
|
Stelara
|
130mg/26mL
|
Concentrate for Solution For Infusion (Iv)
|
Prescription Drug (RX)
|
Type I glass Vial, crimped with aluminum seal with a light green flip-off button x 26mL (Box of 1's). Single Use Vial.
|
-
|
Cilag AG
|
Switzerland
|
|
Johnson & Johnson (Philippines), Inc.
|
|
-
|
02 April 2020
|
02 April 2025
|
| View |
|
BR-1315
|
Pneumococcal Polysaccharide Vaccine, Polyvalent
|
Pneumovax 23
|
Each dose (0.5 mL) contains 25 mcg of each polysaccharide type (types 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, 33F) dissolved in isotonic saline solution containing 0.25% phenol as a preservative.
|
Solution for Injection (I.M./ S.C.)
|
Prescription Drug (RX)
|
Type I Clear glass vial with rubber stopper enclosed in aluminum shell and pastic flip-off cap x 0.5mL (Box of 10's) (commercial and DOH use)
|
-
|
MSD International GmbH T/A MSD Ireland (Carlow)
|
Ireland
|
|
Merck Sharp & Dohme (I.A.) Corporation
|
|
-
|
02 April 2020
|
02 April 2025
|
| View |
|
BR-1316
|
Trastuzumab
|
Herzuma
|
150mg
|
Powder for Concentrate Solution For Infusion (IV)
|
Prescription Drug (RX)
|
Type I Borosilacte glass vial enclosed with chlorobutyl rubber stopper and Aluminum seal with polypropylene flip-off cap (Box of 1's)
|
-
|
Celltrion Inc, Republic of Korea
|
Korea
|
|
Celltrion Healthcare Philippines, Inc.
|
|
-
|
03 April 2020
|
03 April 2025
|
| View |
|
BR-1317
|
Trastuzumab
|
HERZUMA
|
440mg
|
Powder for Concentrate for Solution fro Infusion (IV)
|
Prescription Drug (RX)
|
Type I Borosilacte glass vial enclosed with chlorobutyl rubber stopper and Aluminum seal with polypropylene flip-off cap + Type I borosilicate glass vial enclosed with chlorobutyl rubber stopper and Aluminum seal with polypropylene flip-off cap (20mL Bacteriostatic Water for Injection with 1.1% benzyl alcohol as diluent) (Box of 1's)
|
-
|
Celltrion Pharm, Inc.
|
Korea
|
|
Celltrion Healthcare Philippines, Inc.
|
|
-
|
03 April 2020
|
03 April 2025
|
| View |
BR-1318_PI_01.pdf
|
BR-1318
|
Follitropin Alfa / Lutropin Alfa
|
Pergoveris
|
350 IU/150 IU (0.48mL)
|
Solution For Injection (SC)
|
Prescription Drug (RX)
|
Multidose. 3mL EP/USP Type I pre-filled pen + 5 29G X 1/2" Double-ended needles in a box
|
-
|
Merck Serono S.p.A.
|
Italy
|
|
Merck, Inc.
|
Merck, Inc.
|
-
|
16 April 2020
|
16 April 2025
|
| View |
|
BR-1319
|
Follitropin alfa / Lutropin alfa
|
Pergoveris
|
450 IU/225 IU (0.72 mL)
|
Solution For Injection (SC)
|
Prescription Drug (Rx)
|
Multidose. 3 mL EP/USP Type I pre-filled pen + 7 296 x 12" double-ended needles in a Box.
|
-
|
Merck Serono S.p.A
|
Italy
|
N/A
|
Merck, Inc.
|
Merck, Inc.
|
Variation
|
11 June 2021
|
16 April 2025
|
| View |
|
BR-1320
|
Follitropin alfa / Lutropin alfa
|
Pergoveris
|
900 IU/450 IU (1.44 mL)
|
Solution For Injection (SC)
|
Prescription Drug (Rx)
|
Multidose. 3 mL EP/USP Type I pre-filled pen + 14 29Gx" double-ended needles in a Box.
|
-
|
Merck Serono S.p.A.
|
Italy
|
N/A
|
Merck, Inc.
|
Merck, Inc.
|
Variation
|
11 June 2021
|
16 April 2025
|
| View |
BR-1321_PI_01.pdf
|
BR-1321
|
Botulinum Toxin Type A
|
Nabota
|
200 Units
|
Lyophilized Powder for Solution for Injection (IM/SC)
|
Prescription Drug (RX)
|
USP Type O borosilicate glass vial enclosed with chlorobutyl rubber stopper, crimped with aluminum seal and orange polypropylene cap (Box of 1's)
|
-
|
Daewoong Pharmaceutical Co., Ltd.
|
Korea
|
|
Daewoong Pharma Philippines, Incorporated
|
|
Monitored Release
|
16 June 2020
|
16 June 2025
|
| View |
BR-1323_PI_01.pdf
|
BR-1323
|
Adalimumab
|
Humira
|
20mg/0.2mL
|
Solution For Injection (SC)
|
Prescription Drug (RX)
|
1 Box holds 2 Alcohol swabs and 2 blister, each containing type 1 pre-filled glass syringe x 0.2mL with 29 G 1/2 Needle. Single dose.
|
-
|
Vetter Pharma-Fertigung GmbH & Co. KG
|
Germany
|
|
Zuellig Pharma Corporation
|
|
monitored Release
|
24 June 2020
|
24 June 2025
|